United States Patent 11,633,389 (Methylphenidate Chewable Extended-Plus-Immediate Release): Scope, Claims, and Patent-Strength Assessment
US Drug Patent 11,633,389 claims a racemic methylphenidate chewable tablet that combines (i) a sustained-release component built from a water-insoluble, water-permeable, pH-independent barrier-coated racemic methylphenidate–cation exchange resin complex and (ii) immediate-release methylphenidate delivered either as uncomplexed drug/salt and/or an immediate-release resin complex. The core enforceable scope is the specific architecture: “resin complex + pH-independent water-permeable water-insoluble barrier coat with defined plasticizer content and defined coat weight fraction + tuned split between sustained vs immediate release + defined dissolution and exposure metrics.”
The claims are layered. Independent claim 1 covers a broad “one immediate-release component” configuration plus multiple dependent claims that narrow the barrier chemistry, coat fraction, immediate-release timing, tablet hardness, and pharmacokinetic targets. Independent claim 27 recites a two-immediate-release-component design, including an immediate-release component that is explicitly “uncomplexed” and a second immediate-release component that is explicitly an “immediate release methylphenidate–cation exchange resin complex.”
What does US 11,633,389 claim for a methylphenidate chewable tablet?
Featured snippet answer: US 11,633,389 claims a chewable tablet with a sustained-release resin-complex core protected by a pH-independent, water-permeable water-insoluble barrier coat with plasticizer, paired with an immediate-release component that releases in <30 minutes, with the sustained-release portion accounting for ~50% to ~90% of total racemic methylphenidate and with additional dependent limitations on coat type, coat fraction, and PK/dissolution targets.
Core claim architecture (Claim 1 skeleton)
Claim 1 requires, in combination:
A. Dosage form
- “Methylphenidate chewable tablet” (implies chewability/form factor; additional dependent claims include scorable/divisible and hardness).
B. Sustained-release racemic methylphenidate component
- Contains a “water-insoluble, water-permeable, pH-independent barrier coated, racemic methylphenidate–cation exchange resin complex”
- The complex is dispersed in an optional “polymeric matrix”
- Polymer may be water-insoluble or water-soluble or copolymer.
- Barrier coating is defined by composition and function:
- “water-insoluble, water-permeable, pH-independent polymer and a plasticizer”
- Barrier coat amount: ~20% to ~50% w/w based on the weight of the coated complex–optional matrix
- Barrier is “over” the complex–optional matrix
- Provides the sustained-release profile to the racemic methylphenidate
C. Immediate-release racemic methylphenidate component
- At least one immediate-release component releases in < about 30 minutes (in vitro dissolution)
D. Dose split and excipients
- Sustained-release portion provides ~50% to ~90% w/w of total racemic methylphenidate in the tablet
- Pharmaceutically acceptable excipients
Independent claim 1: practical meaning for design space
Claim 1’s enforceability hinges on three technical “gates”:
-
The sustained-release microstructure
- A methylphenidate–cation exchange resin complex that is barrier-coated with a water-insoluble, water-permeable, pH-independent polymer plus plasticizer.
- The barrier is required to be quantitatively present at ~20% to ~50% w/w of the coated complex–matrix.
-
The sustained-to-immediate drug partition
- Sustained release must account for 50% to 90% of total racemic methylphenidate.
-
The immediate-release dissolution criterion
- Immediate-release must achieve release in <30 minutes by in vitro dissolution.
That combination makes the claim harder to “design around” than broad “extended release methylphenidate” concepts, because it fixes both the carrier chemistry (resin complex + barrier coat properties) and the macroscopic release split plus dissolution performance.
What are the key dependent limitations that narrow US 11,633,389?
Claim 1 has numerous dependent claims that close off variants. Below are the most litigation-relevant narrowing features.
Immediate-release timing and split (Claims 2, 5, 6–11)
- Claim 2: Immediate-release component releases in ~10 minutes (tighter than <30).
- Claim 5: Immediate-release methylphenidate–cation exchange resin complex is ~10% to 20% w/w of total racemic methylphenidate.
- Claim 6: Immediate-release component can be uncomplexed racemic methylphenidate or a pharmaceutically acceptable salt.
- Claims 7–8: For the uncomplexed option:
- uncomplexed drug/salt is ~10% to 20% of total racemic methylphenidate
- specifically includes racemic methylphenidate HCl
- Claim 9: racemic methylphenidate HCl is ~15% w/w of total racemic methylphenidate.
- Claim 10: immediate-release methylphenidate–resin complex at ~15% w/w of total racemic methylphenidate.
- Claim 11: total immediate release components are ~30% w/w.
Design implication: Claims 6–11 provide a “fork” between uncomplexed immediate-release and resin-complex immediate-release, and they also fix amounts. A generic or competitor using uncomplexed immediate-release can fall within those dependent claims if the formulation quantities match.
Sustained-release fraction (Claims 3–4)
- Claim 3: sustained component provides ~60% to ~80% of total racemic methylphenidate.
- Claim 4: sustained component provides ~70%.
Design implication: If a formulation targets ~90% sustained / ~10% immediate, it may avoid the dependent claims but could still fall under claim 1’s broader 50%–90% window.
Barrier coating composition, mechanics, and coat fraction (Claims 13–16, 14–15)
- Claim 13: barrier coating is ~2.5% to ~15% w/w of plasticizer (or combination).
- Claim 14: barrier coating tensile strength ~150% to ~400% and one of three explicit coating system types:
- (a) cured, water-permeable, non-ionic, pH-independent barrier: polyvinyl acetate + stabilizer + plasticizer
- (b) pH-independent acrylic: polymer/copolymer comprising ethyl acrylate + methyl methacrylate
- (c) solvent-based ethylcellulose coating
- Claim 15: for polyvinyl acetate system specifically:
- ~70% to ~90% w/w polyvinyl acetate
- ~2% to ~10% w/w plasticizer
- Claim 16: barrier coating layer is ~25% to ~35% by weight of the coated complex–optional matrix.
Design implication: These dependent claims provide a set of “specific embodiments” that are likely to be used for infringement arguments if an accused product uses PVAc or acrylic systems, and uses tensile strength and plasticizer ranges consistent with the patent.
Tablet mechanical/handling attributes (Claim 12, 19)
- Claim 12: tablet hardness ~8 kp to ~23 kp.
- Claim 19: can be scored and is readily titrated.
- Claim 30 (also claim 29): capable of being divided and retaining extended release profile.
Pharmacokinetics and performance equivalence (Claims 17–18, 21–23, 22, 30)
Key PK windows appear across multiple dependents:
- Claim 17: adults fasted and fed after single 40 mg racemic methylphenidate HCl equivalent:
- AUC0-∞: ~110 to ~140 ng·hr/mL
- Cmax: ~10 to ~15 ng/mL
- Claim 18: single plasma concentration peak.
- Claim 21: includes 90% confidence interval for geometric test/reference ratios of one or more of AUC0-3 or AUC0-4 of FIG. 1.
- Claim 22: methylphenidate plasma concentration curve is equivalent to FIG. 1 from 0 to 8 hours under fasted and fed after single oral administration.
- Claim 23: therapeutically effective amount in <1 hour through ~8 hours in ADHD patients.
- Claim 30: PK includes AUC0-∞ ~110–140 and Cmax ~10–15 for 40 mg equivalent.
Design implication: Competitors can attempt to avoid infringement by achieving different PK outcomes, but that is not a reliable design-around alone because claim 1 is framed around composition and release timing (dissolution <30 min for immediate component, plus sustained fraction and barrier properties). PK claims in dependents typically strengthen the patent’s evidentiary case if performance matches.
Dose strengths (Claims 24–26)
- Tablets comprising equivalents of:
- 40 mg (claim 24)
- 20 mg (claim 25)
- 30 mg (claim 26)
How does independent claim 27 expand or change the scope?
Featured snippet answer: Claim 27 adds a defined two-immediate-release-component structure: one immediate-release component is explicitly uncomplexed racemic methylphenidate/salt, and a second immediate-release component is explicitly an immediate-release methylphenidate–cation exchange resin complex, while the sustained-release component remains the barrier-coated pH-independent resin-complex system with the same barrier/coat/fraction framework.
Claim 27 key differences vs claim 1
Claim 27 requires:
-
Sustained release microstructure is essentially the same: barrier-coated pH-independent water-insoluble, water-permeable barrier + plasticizer over a methylphenidate–cation exchange resin complex in optional polymeric matrix; barrier coat present ~20% to ~50% w/w based on coated complex–optional matrix weight.
-
Immediate release is split into two components:
- First immediate release component:
- provides release in <30 minutes
- comprises uncomplexed racemic methylphenidate or a pharmaceutically acceptable salt
- Second immediate release component:
- comprises an immediate release methylphenidate–cation exchange resin complex
-
Sustained release fraction still required: ~50% to ~90% of total racemic methylphenidate.
-
Excipients remain.
Additional limitation in claim 27 dependents
- Claim 28: barrier plasticizer ~2.5% to ~15% w/w (aligned with claim 13).
- Claim 29: therapeutic window <1 hour to ~8 hours.
- Claim 30: scorable/dividable retains extended release profile and includes PK ranges for 40 mg equivalent.
Design implication: Claim 27 is a stronger lock-in against formulations that use only one immediate-release mechanism. If a competitor uses only uncomplexed immediate-release (no resin complex) or only resin-complex immediate release (no uncomplexed fraction), it may avoid claim 27 but still be captured by claim 1 depending on its configuration.
How strong is the patent estate for this concept (scope strength and likely infringement hooks)?
Strength drivers
- Material specificity: It is not just “extended release methylphenidate.” It requires a particular carrier technology: methylphenidate–cation exchange resin complex plus pH-independent, water-insoluble but water-permeable barrier coating with quantified coat weight fraction and plasticizer fraction.
- Quantified boundaries: The barrier amount, plasticizer content, sustained fraction, and dissolution time are numerically bounded.
- Architecture redundancy: Claim 1 and claim 27 cover multiple immediate-release configurations (at least one immediate component; or two explicit immediate components). This reduces freedom to substitute one immediate-release strategy without risk.
- Performance claims as collateral evidence: PK and dissolution windows appear as dependents, which often become central in litigation once compositional elements are matched.
Primary infringement hooks to expect
For a formulation to land inside the core independent claims, a plaintiff typically needs to show:
- The sustained-release fraction uses a barrier-coated resin complex with the required barrier characteristics.
- The barrier coating meets “pH-independent, water-insoluble, water-permeable” functionality and includes plasticizer and falls within the weight fraction.
- The immediate-release portion meets the <30 minute dissolution criterion.
- The sustained-to-immediate split is within 50%–90% sustained.
A defendant can fight on any of those, but the claim structure gives the patentee multiple technical routes: dissolution testing, barrier composition analysis, coat quantification, and resin-complex identification.
What patent coverage exists against different generic and “next-gen” methylphenidate chewable products?
Scenario mapping against possible design choices
The claims create clear risk categories based on how a competitor formulates.
1) If a generic copies the resin-complex + barrier coat concept
- High risk for claim 1 and often claim 27 if it uses both uncomplexed and resin-complex immediate components.
2) If a competitor uses the same barrier chemistry but changes sustained fraction
- Still potentially within claim 1 if sustained portion remains 50%–90%.
- Avoidance would require moving outside that range.
3) If a competitor changes barrier polymer system (PVAc vs acrylic vs ethylcellulose)
- Claim 14 provides explicit “one of” options, but claim 1 itself already requires a “water-insoluble, water-permeable, pH-independent polymer + plasticizer” barrier.
- Switching polymer class may avoid dependent claim 14 but not necessarily independent claim 1, if the new barrier still matches functional requirements.
4) If a competitor avoids resin complexes entirely in the sustained portion
- That is the most effective design-around conceptually, because the sustained release requires the barrier-coated racemic methylphenidate–cation exchange resin complex.
- But if they use a different ion-exchange system or complex type, claim interpretation and evidence would turn on whether it is still a “cation exchange resin complex.”
5) If a competitor uses a fast-release component that does not meet <30 min dissolution
- It can try to shift dissolution slower and avoid claim 1’s immediate-release requirement.
How does the claim language handle drug form: racemic methylphenidate HCl?
The claims consistently use “racemic methylphenidate” and explicitly include racemic methylphenidate HCl in multiple dependents (claims 8–9). That means salts are within scope; the enforcement target is not limited to a single salt form.
This matters because many methylphenidate products use methylphenidate HCl. A defendant may still practice the patented concept if they use HCl and meet the microstructure and release split.
How does US 11,633,389 interact with FDA approval strategy (Orange Book / ANDA / 505(b)(2))?
This analysis cannot be completed from the information provided. Orange Book listing status, FDA approval dates, listed patents, and any ANDA/505(b)(2) references determine:
- whether 11,633,389 is listed against a specific NDA/ANDA product,
- which products are “at risk” for Paragraph IV,
- and whether the patent is tied to a particular strength (20 mg/30 mg/40 mg equivalents) and dosage form (chewable).
With only the claim text, the regulatory and Orange Book linkage cannot be established to any particular listed drug product, and therefore exclusivity and generic timing cannot be computed here.
Where are the litigation-friction points likely to occur?
1) Proving “pH-independent water-insoluble water-permeable” barrier behavior
Barrier functionality is stated, which typically means the patentee will use:
- dissolution testing under different pH media,
- permeability and dissolution rate comparisons,
- and mechanical property measurements tied to dependent claim 14 tensile strength ranges.
2) Measuring barrier coat amount “based on the weight of the coated complex–optional matrix”
Quantification methods and how weight fractions are calculated will become a focal issue in expert testimony.
3) Demonstrating resin-complex formation vs blending
If an accused product merely includes methylphenidate with resin but not as a complex or not in the barrier-coated configuration, that can be contested.
4) In vitro dissolution endpoint for immediate-release <30 minutes
The “less than about 30 minutes” criterion will be tested across media and apparatus settings. A defendant will try to show their formulation does not reliably release within the required window using the claimed method conditions.
5) PK equivalence dependents (claims 17, 21–23, 22, 30)
If the accused product has different AUC/Cmax ranges or different curve shapes, defendants can push back on dependent-claim infringement even if independent-claim composition matches. Still, independent claims can prevail without matching PK dependents.
Key Takeaways
- US 11,633,389 centers on a chewable methylphenidate tablet combining sustained release from a barrier-coated racemic methylphenidate–cation exchange resin complex and an immediate release fraction meeting <30 minutes dissolution.
- The sustained-release carrier is constrained by barrier functionality (water-insoluble, water-permeable, pH-independent) and quantified coat parameters (about 20%–50% w/w barrier relative to coated complex–optional matrix; plasticizer about 2.5%–15% w/w in dependents).
- Enforcement risk is structural: keeping the same resin-barrier microarchitecture while tuning the split between sustained (about 50%–90%) and immediate release tends to stay within independent claims.
- Claim 27 narrows to formulations using both uncomplexed immediate-release and resin-complex immediate-release in the same tablet, in addition to the barrier-coated sustained-release system.
FAQs
- Does US 11,633,389 cover methylphenidate tablets without a chewable formulation?
- Can a formulation avoid US 11,633,389 by eliminating the immediate-release component that releases in under 30 minutes?
- How do the barrier-coating tensile strength limits (150%–400%) affect infringement risk?
- Is racemic methylphenidate HCl required for claim coverage or only in dependent claims?
- What design choices are most likely to move a product outside the sustained-to-immediate split range (50%–90% sustained)?
References
- United States Patent No. 11,633,389.
